Skip to main content
Premium Trial:

Request an Annual Quote

RXi Acquires Ownership of Previously Licensed RNAi Delivery Technology

Premium

RXi Pharmaceuticals said last week that it has acquired direct ownership of a self-delivering RNAi technology it had previously licensed from Advirna.

In July, RXi announced that it had acquired an exclusive licensed to the technology, which was developed by a Boulder, Colo.-based biotech firm co-founded by the company's CSO (see RNAi News, 7/30/2009).

"By combining this newly acquired technology into RXi's own portfolio and gaining full control of the patent prosecution, we enhance the potential of obtaining broader claims that would further strengthen RXi's intellectual property position," RXi President and CEO Tod Woolf said in a statement.

Terms of the deal with Advirna were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more